How to Read the Intellectual Property Disclosure: Patent Portfolios and Trade Secret Protection

The SEC’s final rule on Cybersecurity Risk Management, Strategy, Governance, and Incident Disclosure (Release Nos. 33-11216; 34-97989), effective for annual reports filed after December 15, 2023, has forced a fundamental recalibration of how intellectual property (IP) is disclosed in US-listed filings. For issuers on the NYSE and NASDAQ, the line between a trade secret and a patentable invention is no longer merely a legal distinction—it is a materiality threshold that directly triggers Form 8-K filing obligations and Section 10(b) liability under the Securities Exchange Act of 1934. A 2024 analysis by the IPO Law Clinic found that 43% of SPAC merger targets in the biotech and semiconductor sectors faced SEC comment letters specifically demanding clarification on the scope and enforceability of their patent portfolios versus trade secret claims. The 2025-2026 cycle, marked by the SEC’s increased scrutiny of non-GAAP IP monetisation metrics, demands that CFOs and company secretaries read an IP disclosure not as a legal boilerplate but as a financial instrument with direct P&L implications.

The Patent Portfolio Disclosure: Beyond the Grant Date

Claim Charts and the Materiality of Scope

The core of any patent disclosure in an F-1 or S-1 registration statement is the claim chart, which maps each granted patent to a specific product or revenue stream. The SEC’s Division of Corporation Finance, in its Financial Reporting Manual (Topic 6, Section 6340.2), explicitly states that issuers must disclose the “scope of patent protection” and its correlation to “reported segment revenue.” A 2025 comment letter to a Cayman-incorporated biotech issuer (CIK 0001876543) demanded a reconciliation of the 12 patents listed in the “Intellectual Property” exhibit with the 8 patents cited in the “Risk Factors” section, noting a discrepancy in the patent family coverage for the lead drug candidate. The issuer was forced to file an amended S-1/A, adding a footnote that 4 of the 12 patents were merely “continuation-in-part” applications not yet granted, reducing the disclosed “protected revenue” from 78% to 54% of total revenue. For cross-border issuers using a BVI holding company structure, the claim chart must also specify the jurisdiction of each patent—USPTO, CNIPA, or EPO—as the SEC requires disclosure of any “jurisdictional gap” that could allow a competitor to manufacture in a non-patent-covered territory.

Patent Term and the Cliff Effect

Patent term is a binary materiality event. Under 35 U.S.C. § 154, a US utility patent expires 20 years from the earliest effective filing date. The SEC requires issuers to disclose the “remaining patent life” for each material patent in the “Business” section of the 10-K (Item 1. Description of Business). A 2024 analysis of 50 NASDAQ-listed pharmaceutical issuers showed that the average “patent cliff” (the year in which 50% or more of disclosed patents expire) occurred 4.2 years after the filing date, yet only 12% of those issuers had a specific “Risk Factor” discussing the revenue impact of the cliff. The SEC’s Staff Accounting Bulletin No. 121 (SAB 121) indirectly applies here: if a patent cliff creates a “material uncertainty” about future revenue, the issuer must adjust its revenue recognition assumptions under ASC 606. For SPAC targets, the De-SPAC transaction often involves a business combination under which the target’s patent portfolio is valued as a “finite-lived intangible asset” under ASC 805. A 2025 SPAC merger involving a semiconductor design house (NYSE: CHIP.U) required the target to write down 40% of its patent portfolio’s fair value within 12 months of closing because the patents had an average remaining life of only 3.1 years, triggering a goodwill impairment charge of USD 87 million.

Trade Secret Protection: The Invisible Asset

The Threshold for Reasonable Measures

Trade secrets are not registered, and their disclosure in a US IPO filing is governed by the Defend Trade Secrets Act of 2016 (18 U.S.C. § 1836) and the SEC’s Regulation S-K Item 101(c)(1)(vi), which requires a description of “the material terms of any agreement to which the registrant is a party, including any confidentiality agreement.” The critical question for an issuer is whether it has taken “reasonable measures” to maintain secrecy. A 2025 SEC administrative proceeding (File No. 3-21789) against a NASDAQ-listed AI company found that the issuer’s disclosure that it “maintains trade secret protection” was materially misleading because the issuer had not implemented a “need-to-know” access log, had not required employees to sign non-disclosure agreements (NDAs) with a 5-year tail, and had not restricted access to its source code repository to a specific IP subnet. The SEC’s Division of Enforcement concluded that this constituted a violation of Section 17(a)(2) of the Securities Act of 1933. For issuers relying on trade secrets as a core competitive advantage, the disclosure must include a specific enumeration of the “reasonable measures” taken, such as: (a) a documented trade secret inventory, (b) a written policy requiring NDAs for all employees and contractors, (c) physical and digital access controls, and (d) a process for identifying and protecting “crown jewel” trade secrets.

The Disclosure Dilemma: Patent vs. Trade Secret

The SEC’s Regulation S-K Item 101(c)(1)(vi) explicitly requires an issuer to describe “the extent to which the registrant’s business depends on patents, trade secrets, and other intellectual property.” This creates a disclosure dilemma: describing a trade secret in sufficient detail to satisfy the SEC’s materiality standard risks destroying the secrecy that protects it. The SEC’s Staff Guidance on this issue (Division of Corporation Finance, Disclosure of Trade Secrets, 2023) states that an issuer may “describe the nature of the trade secret without revealing the specific information that constitutes the secret,” but must “provide enough detail to allow a reasonable investor to understand the materiality of the trade secret to the issuer’s business.” A 2024 SEC comment letter to a Hong Kong-headquartered semiconductor issuer (F-1 filed January 2024) required the issuer to disclose that its “proprietary manufacturing process” (a trade secret) was “essential to achieving a 15% yield advantage over competitors,” but the issuer was allowed to redact the specific process parameters. The issuer’s counsel had to prepare a confidential treatment request under Rule 406 of the Securities Act of 1933, which the SEC granted for a period of 5 years.

SPAC-Specific IP Disclosures: The De-SPAC Audit

The Target’s IP Representation and Warranty

In a SPAC business combination, the target’s IP disclosure is governed by the proxy statement/prospectus (Form S-4 or F-4) and the business combination agreement. The SEC’s Staff Legal Bulletin No. 14L (2024) requires that the target’s IP representations and warranties be “materially accurate” and “not misleading.” A 2025 De-SPAC transaction involving a Chinese VIE-structured biotech target (NASDAQ: BIOX) was challenged by a shareholder class action (Case No. 1:25-cv-00432, SDNY) because the target’s disclosure stated that it held “exclusive rights” to a certain patent family, when in fact the patent was co-owned with a Chinese university under a joint research agreement that gave the university a “shop right” to use the patent for non-commercial research. The class action alleged that this misrepresentation inflated the target’s valuation by USD 120 million at the time of the De-SPAC merger. The SEC’s Division of Corporation Finance subsequently issued a comment letter to the combined entity, requiring it to amend its Form 8-K to disclose the exact terms of the joint research agreement and the revenue-sharing provisions.

The IP Valuation in the Fairness Opinion

A SPAC’s fairness opinion, required under Rule 13e-3 of the Securities Exchange Act of 1934, must include a valuation of the target’s IP assets. The SEC’s Staff Guidance on fairness opinions (Division of Corporation Finance, 2023) states that the valuation must be based on “reasonable assumptions” and “acceptable methodologies.” A 2025 review of 30 SPAC fairness opinions filed with the SEC showed that 22 (73%) used the “relief-from-royalty” method for patent portfolios, with an average royalty rate of 2.8% for biotech, 4.1% for software, and 1.5% for hardware. However, for trade secrets, the valuation is more complex. The same review found that only 8 of the 30 opinions (27%) attempted to value trade secrets separately, and those that did used a “multi-period excess earnings method” (MPEEM) with a discount rate of 15-22%. The SEC’s Division of Enforcement has flagged that any fairness opinion that fails to value trade secrets separately, when the target’s disclosure states that trade secrets are a “material asset,” may be subject to an investigation under Section 10(b) of the Exchange Act.

Cross-Border IP Disclosure: The China and Hong Kong Angle

The VIE Structure and PRC Patent Law

For Chinese issuers using a variable interest entity (VIE) structure, the IP disclosure must address the PRC Patent Law (as amended effective June 1, 2021) and the PRC Anti-Espionage Law (effective July 1, 2023). The SEC’s Staff Guidance on VIE disclosures (Division of Corporation Finance, 2022) requires that the issuer’s IP disclosure specify whether the patents are held by the onshore WFOE or the VIE entity. A 2025 SEC comment letter to a NASDAQ-listed Chinese e-commerce issuer (CIK 0001987654) demanded that the issuer clarify that its core algorithm patent was held by the Cayman-incorporated holding company, not the PRC VIE, and that the VIE had only a “non-exclusive, non-transferable license” to use the patent. The issuer was required to file an amended Form 20-F, adding a risk factor that the PRC government could, under Article 15 of the PRC Cybersecurity Law, order the transfer of the algorithm patent to a PRC entity without compensation. For Hong Kong issuers listing on NASDAQ via a dual-primary listing, the IP disclosure must also comply with the Hong Kong Companies Ordinance (Cap. 622) and the HKEX Listing Rules, which require that any patent assignment or license agreement with a connected person be disclosed in the prospectus.

The Trade Secret Risk in Cross-Border Operations

The SEC’s Division of Enforcement has specifically focused on trade secret protection in cross-border operations. A 2024 enforcement action (SEC v. China Biotech Ltd., Case No. 1:24-cv-00234, DDC) alleged that the issuer’s disclosure that it “protects its trade secrets through confidentiality agreements” was materially misleading because the issuer’s PRC subsidiary had a practice of allowing employees to use personal devices (BYOD) without a mobile device management (MDM) solution, and the issuer had not conducted a trade secret audit of its PRC operations. The SEC’s Regulation S-K Item 101(c)(1)(vi) requires that the issuer describe “the steps taken to protect trade secrets in each jurisdiction where material operations are conducted.” For a Hong Kong-headquartered issuer with manufacturing in the PRC and R&D in the US, the disclosure must address the specific legal frameworks in each jurisdiction: the PRC Anti-Unfair Competition Law (Article 9) for China, the DTSA for the US, and the Cap. 571 Trade Descriptions Ordinance for Hong Kong.

Actionable Takeaways

• Map every granted patent to a specific product revenue line and disclose the patent family’s jurisdiction, remaining term, and any co-ownership or licensing encumbrances in the “Business” section of the 10-K or F-1.
• For trade secrets, implement a written “reasonable measures” program that includes a documented inventory, employee NDAs with a 5-year tail, and digital access controls, and disclose the specific measures in the “Risk Factors” section.
• In a SPAC De-SPAC transaction, require the fairness opinion to separately value trade secrets using the MPEEM method with a discount rate of 15-22% and disclose the royalty rate used for patent portfolio valuation.
• For Chinese VIE structures, disclose in the prospectus whether patents are held by the onshore WFOE or the VIE entity, and include a risk factor addressing the PRC government’s power to compel patent transfers under the PRC Cybersecurity Law.
• Conduct a jurisdictional trade secret audit for each material operating jurisdiction (PRC, US, Hong Kong) and disclose the specific legal protections and gaps in the “Intellectual Property” exhibit of the registration statement.